Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Castrate-resistant prostate cancer (CRPC) is an advanced, fatal stage of prostate cancer.
• The mechanisms driving androgen receptor (AR) reactivation in CRPC remain incompletely understood.
• Androgen deprivation therapy (ADT) is a primary treatment, but resistance develops.

Purpose of the Study:

• To investigate the role of the receptor tyrosine kinase RON in prostate cancer progression and androgen receptor signaling.
• To determine how RON influences cellular properties and gene expression in different prostate cancer contexts.
• To explore RON as a potential therapeutic target in CRPC.

Main Methods:

• Analysis of RON's function as a transcription factor and its effect on cellular mechanical properties.
• Investigation of RON's interaction with the androgen receptor (AR) signaling pathway.
• Assessment of RON expression in various prostate cancer cell lines (LNCaP, C4-2B, DU145, PC-3) and clinical samples.

Main Results:

• RON alters cell mechanical properties, influencing epithelial-to-mesenchymal transition.
• RON differentially regulates AR signaling: it inhibits AR in androgen-responsive cells but activates AR-regulated genes in castrate-resistant and AR-negative cells.
• RON expression is significantly elevated in CRPC tumors and its activation is linked to androgen independence.

Conclusions:

• RON plays a dual role in AR signaling, potentially promoting androgen independence in advanced prostate cancer.
• RON activation is a key event in CRPC development.
• Inhibiting RON concurrently with AR antagonists presents a promising therapeutic strategy for hormone-refractory prostate cancer.